136 results
Page 2 of 7
8-K
EX-99.1
3h5v09vbd1s71 ctuk1
16 Dec 22
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
8:17am
8-K
EX-99.1
w5xwqxjfld m7stv
16 Nov 22
Corporate OverviewNovember 2022At the Forefront of Therapies for Rare Diseases
7:01am
424B5
o9zxsnowv01yd8468
7 Nov 22
Prospectus supplement for primary offering
7:11am
8-K
EX-99.1
vgy08r8 bpecd2
14 Sep 22
Corporate Overview September 2022 At the Forefront of Therapies for Rare Diseases
7:00am
8-K
EX-99.1
zyp1wv9xgq82t
10 Jan 22
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
7:00am
S-3ASR
i8sop5o1tudt0
9 Nov 21
Automatic shelf registration
5:05pm
8-K
EX-99.3
6xf v3umbv4v
29 Sep 21
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV
9:28am
8-K
EX-99.1
zilg5ee 5m
2 Aug 21
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
7:00am
8-K
EX-99.1
dhcyjlyl4tc jp60
8 Jun 21
Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA
7:00am
S-3ASR
fny3s56e480tt7xb
2 Feb 21
Automatic shelf registration
8:11am